HeartBeam Named Contributing Partner In Launch Of EXIT-CVD Research Project, Co-Funded By European Union Innovative Health Initiative And Industry Partners

• HeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortium
• HeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studies
• HEART-CHECK will evaluate whether HeartBeam’s at-home 3D ECG can help clinicians recognize recurrent events earlier in patients recently discharged after ACS

HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced it is a contributing partner in the launch of the EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative (IHI) and industry partners. The research consortium is led by University Medical Center Groningen (UMCG) and Royal Philips, and aims to transform how cardiovascular disease is detected, monitored and treated.

Within EXIT-CVD, the HEART-CHECK study will evaluate the HeartBeam System for early detection and triage of cardiac events in high-risk patients recently discharged after an acute coronary syndrome (ACS), a group with well-documented risk of recurrent ischemic events, arrhythmias and hospital readmissions.